Monopar Therapeutics: Radiopharmaceuticals And Rare Disease Potential In Focus

Monopar Therapeutics Inc. (NASDAQ: MNPR ) develops radiopharmaceutical solutions to address the unmet medical needs of cancer patients and, more recently, rare diseases. MNPR integrates radiodiagnostics and radiotherapeutics to visualize and kill cancer cells. MNPR has MNPR-101-Zr, an imaging agent. Similarly, MNPR-101-Lu and MNPR-101-Ac are radiation-basedMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ec ...